Concepedia

Author

Patrick Mouret

Thrombosis Research Institute

Also Known As

Hilton Obenzinger, Mouret, P, P MOURET, P Mouret, P. MOURET, P. Mouret, Patrick Mouret

50

Publications

2.4K

Citations

16

H-Index

27

Concepts

All Affiliations

Thrombosis Research InstituteKlinikum Frankfurt HöchstSahlgrenska University HospitalUniversity of PerugiaHôpital Cochin
PM

About

Patrick Mouret is an author at Thrombosis Research Institute specializing in medicine, thrombosis, and orthopaedics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

9

9

1.5K

2

Orthopaedics

6

6

1.4K

3

Health Sciences

2

2

68

4

Pharmacology

2

2

293

5

Pathology

1

1

23

Patrick Mouret

×

16

Publications

2.4K

Citations

16

H-Index

YearCitations

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

Ajay K. Kakkar, Benjamin Brenner, Ola E. Dahl,

The Lancet

2008

1.1K

A Comparison of Recombinant Hirudin with a Low-Molecular-Weight Heparin to Prevent Thromboembolic Complications after Total Hip Replacement

Bengt I. Eriksson, Peter Kälebo, Patrick Mouret,

New England Journal of Medicine

1997

371

Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement

Giancarlo Agnelli, Alexander T. Cohen, Ola E. Dahl,

Thrombosis and Haemostasis

2003

252

The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study

Bengt I. Eriksson, Giancarlo Agnelli, Alexander T. Cohen,

Journal of Thrombosis and Haemostasis

2003

199

Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery

Charles Marc Samama, Silvy Laporte, Nadia Rosencher,

New England Journal of Medicine

2020

96

Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran

Giancarlo Agnelli, Bengt I. Eriksson, Alexander T. Cohen,

Thrombosis Research

2008

94

Venous Thromboembolism (VTE) Prevention with Semuloparin in Cancer Patients Initiating Chemotherapy: Benefit-Risk Assessment by VTE Risk in SAVE-ONCO

Daniel J. George, Giancarlo Agnelli, Ajay K. Kakkar,

Blood

2011

54

Preoperative Enoxaparin Versus Postoperative Semuloparin Thromboprophylaxis in Major Abdominal Surgery

Ajay K. Kakkar, Giancarlo Agnelli, Daniel J. George,

Annals of Surgery

2013

38

Extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery – the SAVE-HIP3 study

W. D. Fisher, Giancarlo Agnelli, Daniel J. George,

The Bone & Joint Journal

2013

35

The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study.

Giancarlo Agnelli, Dan George, Winfield S. Fisher,

Journal of Clinical Oncology

2011

33

Page 1